Real-life experience of managing vulval erosive lichen planus: a case-based review and U.K. multicentre case note audit

Simpson, Rosalind; Littlewood, S.M.; Cooper, Susan M.; Cruickshank, Margaret; Green, C.M.; Derrick, E. K.; Yell, Jennifer; Chiang, N.; Bell, Hazel Κ.; Owen, Caroline M.; Javed, Amit; Wilson, Caroline; McLelland, Janet; Murphy, Ruth

doi:10.1111/j.1365-2133.2012.10919.x

Cited by 63 publications

(76 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a prospective cohort study with a mean period of treatment and follow-up of 72 months, one of 114 adults with erosive VLP (0.8%) developed a vulvar squamous cell carcinoma, while two other patients had an oral and a perianal SCC, respectively [46]. It is likely that VLP, like VLS, does not directly turn into SCC and that a precursor stage is necessary (differentiated VIN, acanthotic LP or usual VIN) [47]. Precursor lesions or squamous cell carcinoma (SCC) should be suspected in the case of focal resistance to UPTCS such as white plaques and indurated or granulated ulcers.…”

Section: Evolutionmentioning

confidence: 97%

Vulvar dermatosis

Moyal‐Barracco¹,

Wendling²

2014

Best Practice & Research Clinical Obstetrics & Gynaecol

View full text Add to dashboard Cite

Vulvar dermatoses are inflammatory conditions responsible for chronic or recurrent itching and soreness. The lesions are either circumscribed to the vulva or associated with extragenital localizations which may help to assess the diagnosis. They should be differentiated from infectious or neoplastic diseases which may have clinical similarities. As opposed to the majority of all dermatoses that have a benign and regular course, lichen sclerosus or lichen planus could exceptionally foster the occurrence of an epithelial cancer precursor which may evolve to squamous cell carcinoma. Topical corticosteroids are the mainstay treatment of vulvar dermatosis. We do not know if the treatment of vulvar lichen sclerosus and vulvar lichen planus prevents squamous cell carcinoma.

show abstract

Section: Evolutionmentioning

confidence: 97%

Vulvar dermatosis

Moyal‐Barracco¹,

Wendling²

2014

Best Practice & Research Clinical Obstetrics & Gynaecol

View full text Add to dashboard Cite

show abstract

“…Up to date 10 cases have been described [27,28,29,30,31,32,33,34,35]. Erosive LP is a painful variant of LP with eroded or ulcerated lesions mainly in mucocutaneous sites which is often difficult to treat and may lead to scarring [36,37,38]. Lichen planus pemphigoides refers to a cross-over syndrome of LP and bullous pemphigoid [5] and associations with drug intake have been described (PUVA [39], UVB, paracetamol or ibuprofen [40], simvastatin [41] and ramipril [42,43]).…”

Section: Discussionmentioning

confidence: 99%

Oral, Esophageal and Cutaneous Lichen Ruber Planus Controlled with Alitretinoin: Case Report and Review of the Literature

Kolios¹,

Maggio²,

Gubler

et al. 2013

Dermatology

View full text Add to dashboard Cite

Background: Therapy-resistant lichen planus (LP) can be a challenging condition for dermatologists. There are some case reports about successful treatments with alitretinoin of cutaneous and oral, but not of esophageal LP. Objective: We present the unique case of a patient with cutaneous, oral and esophageal LP which was refractory to classical treatment options (topical clobetasol propionate and pimecrolimus, intramuscular triamcinolone acetonide); because of systemic side effects the patient did not tolerate systemic acitretin dosed up to 25 mg daily. Methods: Oral alitretinoin was used at a dose of 30 mg daily. Results: Both oral and skin changes as well as dysphagia completely resolved within 4 weeks without any severe side effects and the drug was used for 6 months. No papules, intraoral striae or dysphagia recurred during the 6 months of treatment. After 4 months the patient relapsed with mucosal patches so that a second cycle was initiated for 6 months where oral LP lesions resolved after 4 weeks also (with sporadic mild headache). Conclusion: Further studies are needed to better understand the impact of alitretinoin in LP. Our observation suggests alitretinoin as a new, well-tolerated treatment option for esophageal LP after failed response to conventional treatments.

show abstract

“…In addition to the studies acknowledged by Bradford and Fischer, there are 3 other published case series that describe the treatment of mucosal lichen planus in cohorts of more than 50 patients. Simpson et al [5] published a UK multicenter audit of management of 172 patients comparing clinical practice to a proposed standard of optimal care, as well as collecting additional data. Helgesen et al [6] describe treatment response along with clinical features in 58 patients, and Anderson et al [7] discuss the response to hydrocortisone suppositories of 60 patients with vaginal lichen planus.…”

Section: To the Editormentioning

confidence: 99%